{"id":"NCT00619957","sponsor":"Warner Chilcott","briefTitle":"Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis","officialTitle":"Two-year Study to Determine the Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis for 2 Years Followed by a 2 Year Open Label Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-06","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2008-02-21","resultsPosted":"2011-10-28","lastUpdate":"2011-10-28"},"enrollment":285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Other Osteoporosis"],"interventions":[{"type":"DRUG","name":"Placebo tablet","otherNames":[]},{"type":"DRUG","name":"Risedronate","otherNames":[]}],"arms":[{"label":"1","type":"PLACEBO_COMPARATOR"},{"label":"Risedronate","type":"EXPERIMENTAL"}],"summary":"Two year study to determine the safety and efficacy of weekly 35 mg Risedronate doses in men with osteoporosis followed by a two year follow-up study.","primaryOutcome":{"measure":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD), 24 Months/Endpoint, ITT Population.","timeFrame":"Baseline to 24 Months/Endpoint","effectByArm":[{"arm":"Placebo","deltaMin":1.22,"sd":null},{"arm":"Risedronate","deltaMin":5.75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"30 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":23,"countries":["United States","Australia","Belgium","Czechia","France","Hungary","Lebanon","Netherlands","Poland","United Kingdom"]},"refs":{"pmids":["22750403"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":93},"commonTop":["Nasopharyngitis","Arthralgia","Back Pain","Constipation","Hypertension"]}}